CELL TRANSPLANTATION IN THE COVID-19 TREATMENT PROGRAM

Abstract

Cell transplantation for the correction of urgent conditions not associated with
hematological practice and neuroprotection remains a poorly studied area of transplantology
[4]. There is a small pool in the scientific literature articles devoted to this method in the
treatment of peritonitis, pancreatic necrosis, sepsis, DIC. Syndrome acute diffuse alveolar
damage niche for applying the possibilities of discrete cell transplantation is a relatively
new area of research. One of the essential reasons for initiation such works were epidemic
outbreaks of coronavirus severe acute respiratory syndrome (SARS; Severe Acute
Respiratory Syndrome, SARS) 2002 (SARS-CoV) and 2012 (Middle East Respiratory
Syndrome, MERS) years [1,2,3]. Theoretical and experimental foundations of this
types of therapeutic effects in DAP were developed in the first decade of the current
century.